5.29
+0.26(+5.17%)
Currency In USD
| Previous Close | 5.03 |
| Open | 5.05 |
| Day High | 5.33 |
| Day Low | 5.04 |
| 52-Week High | 67.5 |
| 52-Week Low | 4.11 |
| Volume | 132,523 |
| Average Volume | 154,574 |
| Market Cap | 16.89M |
| PE | -0.22 |
| EPS | -24.28 |
| Moving Average 50 Days | 4.88 |
| Moving Average 200 Days | 10.54 |
| Change | 0.26 |
If you invested $1000 in Cellectar Biosciences, Inc. (CLRB) 10 years ago, it would be worth $0.06 as of September 10, 2025 at a share price of $5.29. Whereas If you bought $1000 worth of Cellectar Biosciences, Inc. (CLRB) shares 5 years ago, it would be worth $15.74 as of September 10, 2025 at a share price of $5.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
GlobeNewswire Inc.
Yesterday at 12:05 PM GMT
Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue a
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
GlobeNewswire Inc.
Sep 05, 2025 12:45 PM GMT
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that J
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
GlobeNewswire Inc.
Sep 03, 2025 12:05 PM GMT
FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the ac